Results 51 to 60 of about 6,036 (190)

Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials

open access: yes, 2000
Background. Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk should emergency coronary surgical procedures be required.Methods.
Despotis, GJ   +11 more
core   +1 more source

Efficacy and Safety of Tirofiban for the Management of Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials (RCTs)

open access: yesBrain and Behavior, Volume 16, Issue 6, June 2026.
Graphical representation of the comparative efficacy and safety of intravenous tirofiban for acute ischemic stroke in randomized controlled trials. ABSTRACT Background: Tirofiban is a GP IIb/IIIa inhibitor, an anti‐platelet drug that is used in ischemic stroke or acute coronary syndromes.
Dorothy Lim Bullecer   +12 more
wiley   +1 more source

Abciximab in the treatment of coronary artery disease [PDF]

open access: yes, 2013
Antiplatelet therapy constitutes a cornerstone in the strategies aimed at the effective management of acute coronary syndrome. Abciximab is the oldest and most commonly used intravenous antiplatelet agent in this context, in particular when an invasive ...
Maxwell, Ryan   +2 more
core   +2 more sources

Trombose de seio dural: relato de caso Dural sinus thrombosis: case report

open access: yesArquivos de Neuro-Psiquiatria, 2006
Relata-se o caso de uma gestante de 24 anos, encaminhada ao serviço de neurologia por apresentar agitação, alucinações, confusão mental, cefaléia, perda de visão, afasia e convulsões.
Asdrubal Falavigna   +2 more
doaj   +1 more source

Self-Reporting Theranostic: Nano Tool for Arterial Thrombosis

open access: yesBioengineering, 2023
Arterial thrombosis (AT) originates through platelet-mediated thrombus formation in the blood vessel and can lead to heart attack, stroke, and peripheral vascular diseases.
Suryyani Deb   +6 more
doaj   +1 more source

Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review

open access: yesRevista Portuguesa de Cardiologia, 2019
This article reviews the major pharmacologic features of, and clinical evidence on, adjuvant medical therapy in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention.
Daniel Caldeira, Hélder Pereira
doaj   +1 more source

Stent Thrombosis: A Narrative Review From Pathophysiology to Therapy

open access: yesClinical Cardiology, Volume 49, Issue 4, April 2026.
Stent thrombosis remains a life‐threatening complication of PCI driven by complex interactions between stent design, procedural factors, thrombogenic milieu, and inflammation. This review integrates pathophysiological mechanisms with contemporary and emerging therapeutic strategies, highlighting optimized PCI, tailored antithrombotic therapy, and novel
Emanuele Cecchi   +8 more
wiley   +1 more source

Abciximab for thrombolysis during intracranial aneurysm coiling [PDF]

open access: yes, 2018
Introduction: Thrombotic events are a common and severe complication of endovascular aneurysm treatment with significant impact on patients' outcome.
Lalloo, Shivendra   +6 more
core  

Distinct Thromboxane A₂–Dependent Pathways Regulate Arachidonic Acid–Triggered VASP Phosphorylation at Ser239 and Ser157 in Human Platelets: Real‐Time Visualization Reveals Superior Antithrombotic Efficacy by Targeting Thromboxane A₂ Signaling over Cyclooxygenase Inhibition

open access: yesJournal of Cellular Physiology, Volume 241, Issue 3, March 2026.
ABSTRACT Platelets, as anucleate blood cells, play a pivotal role in the pathogenesis of cardiovascular diseases (CVDs), making antiplatelet therapy essential for preventing thrombotic events such as myocardial infarction. Thromboxane A₂ (TXA₂) is a key pro‐aggregatory mediator that drives platelet activation.
Joen‐Rong Sheu   +6 more
wiley   +1 more source

Time and Dose Dependent Augmentation of Inhibitory Effects of Abciximab by Aspirin

open access: yes, 2001
SummaryAspirin and abciximab independently decrease the incidence of cardiac events. To identify potential interactions, antiplatelet effects of abciximab were characterized in blood from healthy subjects given aspirin. Platelet activation was determined
David Schneider   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy